Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04425291
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:47.034837+00:00
Published At
2022-02-25T00:00:00+00:00
Record Updated At
2022-02-25
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cervical Cancer", "Vulvar Cancer", "Vaginal Cancer", "CIN1", "CIN2", "CIN3", "VaIN1", "VaIN2", "VaIN3", "Genital Wart", "VIN 1", "VIN 2", "VIN 3", "AIS"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-02-25"
protocolSection.identificationModule.nctId
"NCT04425291"
protocolSection.identificationModule.officialTitle
"A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Vulvar Cancer (protocolSection.conditionsModule.conditions)
  • Vaginal Cancer (protocolSection.conditionsModule.conditions)
  • CIN1 (protocolSection.conditionsModule.conditions)
  • CIN2 (protocolSection.conditionsModule.conditions)
  • CIN3 (protocolSection.conditionsModule.conditions)
  • VaIN1 (protocolSection.conditionsModule.conditions)
  • VaIN2 (protocolSection.conditionsModule.conditions)
  • VaIN3 (protocolSection.conditionsModule.conditions)
  • Genital Wart (protocolSection.conditionsModule.conditions)
  • VIN 1 (protocolSection.conditionsModule.conditions)
  • VIN 2 (protocolSection.conditionsModule.conditions)
  • VIN 3 (protocolSection.conditionsModule.conditions)
  • AIS (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.